Related Experiment Video
Updated: Jul 13, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
How could pharmacogenomics help improve patient survival?
Rafael Rosell1, Enriqueta Felip, Luis Paz-Ares
1Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n 08916 Badalona (Barcelona), Spain. rrosell@ico.scs.es
Lung Cancer (Amsterdam, Netherlands)
|October 11, 2007
Summary
Tailoring chemotherapy for non-small cell lung cancer (NSCLC) using genetic markers improves patient outcomes. Specific mutations and gene expression predict response to targeted therapies and chemotherapy, guiding personalized treatment strategies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) treatment is evolving with increased understanding of its genetic landscape.
- Personalized medicine approaches are crucial for optimizing chemotherapy regimens and patient survival.
- Predictive markers are increasingly utilized in specialized centers to guide NSCLC management.
Purpose of the Study:
- To review the role of genetic markers in predicting chemotherapy response in NSCLC.
- To highlight the impact of specific mutations and gene expression on treatment outcomes.
- To present a hypothetical model for customizing chemotherapy in NSCLC.
Main Methods:
- Review of current literature on genetic markers and NSCLC treatment response.
- Analysis of predictive value of epidermal growth factor receptor (EGFR) mutations for tyrosine kinase inhibitors.
- Evaluation of DNA repair markers (ERCC1, RRM1, BRCA1) and XRCC3 mutations in relation to chemotherapy.
- Assessment of 14-3-3sigma methylation in circulating tumor DNA for predicting response.
Main Results:
- Epidermal growth factor receptor (EGFR) tyrosine kinase mutations predict response to gefitinib and erlotinib.
- Methylation of 14-3-3sigma in serum DNA indicates response to cisplatin/gemcitabine.
- Low expression of ERCC1, RRM1, and BRCA1 mRNA predicts improved survival with cisplatin/gemcitabine.
- The Met/Met mutation in XRCC3 240 is associated with significantly better survival.
Conclusions:
- Genetic profiling of NSCLC enables tailored chemotherapy regimens for improved patient outcomes.
- Predictive markers, including specific mutations and gene expression levels, are vital for customizing treatment.
- Personalized treatment strategies based on molecular markers enhance survival and response rates in NSCLC subgroups.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...